First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
[HTML][HTML] Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of …
A Pluzanski, M Krzakowski, D Kowalski… - ESMO open, 2020 - Elsevier
Background First-generation or second-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) are commonly used in EGFR-mutation-positive advanced …
tyrosine kinase inhibitors (TKIs) are commonly used in EGFR-mutation-positive advanced …
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …
YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
[HTML][HTML] The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
[HTML][HTML] Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine …
SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR …
E Nadler, M Pavilack, JL Espirito, J Clark… - Advances in …, 2020 - Springer
Introduction Epidermal growth factor receptor (EGFR) mutations are observed in
approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is …
approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is …
[HTML][HTML] Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a …
Materials And Methods We performed a meta-analysis of the main randomized clinical trials
evaluating the currently approved EGFR-TKIs in first-line of treatment of EGFR-positive …
evaluating the currently approved EGFR-TKIs in first-line of treatment of EGFR-positive …
RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung …
J Liu, Z Sheng, Y Zhang, G Li - Targeted oncology, 2016 - Springer
Objective To determine the efficacy of first-generation epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non …
tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
相关搜索
- large real world cohort
- egfr tyrosine kinase inhibitors
- large cohort growth factor
- treatment patterns kinase inhibitors
- meta analysis lung cancer
- outcome assessment lung cancer
- clinical outcomes growth factor
- egfr mutation asian patients
- clinical outcomes egfr mutations
- egfr tyrosine treatment patterns
- clinical outcomes large cohort
- clinical outcomes t790m mutation